EP2989082A1 — Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
Assigned to Lek Pharmaceuticals dd · Expires 2016-03-02 · 10y expired
What this patent protects
The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -benzo[ d ]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopure ( R )-8-chloro-1-methyl-2,3,4,5-tet…
USPTO Abstract
The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -benzo[ d ]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopure ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -benzo[ d ] azepine or its ( S )-enantiomer, in order to avoid or overcome chemical optical resolution.
Drugs covered by this patent
- Augtyro (REPOTRECTINIB) · Bristol
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.